OBJECTIVE： To systematically review the effect of Xuebijing injection on inflammatory mediators in patients with severe acute pancreatitis （SAP）， and provide evidence-based reference for clinic. METHODS： Retreived from PubMed、CJFD， CBM， VIP and Wanfang Database， randomized controlled trials （RCT） about the effect of Xuebijing injection on inflammatory mediators in patients with SAP were collected. Meta-analysis was performed by using Rev Man 5.2 software after data extraction and bias risk evaluation. RESULTS： Totally 10 RCTs， involving 811 patients. Results of Met-analysis showed， Xuebijing injection can significantly reduce IL-1[SMD＝1.22，95％CI（0.64，1.79），P＜0.001]，IL-6[SMD＝1.86，95％CI（1.46，2.27），P＜0.001]，IL-8 [SMD＝2.16，95％CI（1.45，2.88），P＜0.001]，TNF-α[SMD＝2.16，95％CI（1.56，2.76），P＜0.001]，C-reactive protein [SMD＝1.63， 95％CI（0.56，2.70），P＜0.001] and endotoxin [SMD＝2.39，95％CI（1.33，3.45），P＜0.001]， and it also can significantly improve IL-10[SMD＝－2.75，95％CI（－3.84，－1.67），P＜0.001]， with statistical significance. CONCLUSIONS： Based on conventional trecotment，Xuebijing injection can significantly improve inflammatory mediators in patients with SAP.